Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection

Jaeckel, Elmar; Cornberg, Markus; Santantonio, T.; Mayer, Julika; Wedemeyer, Heiner; Zankel, M.; Pastore, G; Manns, Michael P.

doi:10.1016/s0016-5085(08)82820-x

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In any case, detailed investigation of how cytokine-infused collagen gels should be used to maximize therapeutic effects and minimize side effects would likely require larger animal experiments and more accurate methods of assessment, such as in vivo fluorescence, microCT, or ultrasound imaging. 41−43 Similarly, more experiments are needed to evaluate whether IFNA2b-CBD, by itself or incorporated in collagen matrices, is suitable to treat other diseases such as hepatitis, [4][5][6]11 against which IFNA2b is already used. Currently, biomaterials have shown potentials in antitumor therapies, 44 mostly as drug carriers in the forms such as hydrogels 45,46 and nanoparticles.…”

Section: ■ Discussionmentioning

confidence: 99%

Collagen Hydrogel Functionalized with Collagen-Targeting IFNA2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors

Jiang

et al. 2018

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Interferon alpha 2b (IFNA2b) has been used in immunotherapy for cancers with certain success. To reduce fast diffusion of IFNA2b and consequent dose-dependent side effects, we constructed a collagen hydrogel loaded with IFNA2b fused to collagen-binding domain by using methods of tissue engineering. The fusion protein showed apoptotic activity similar to that of native IFNA2b against MCF-7 cells in vitro, but with relatively higher affinity for collagen type I. Accordingly, the former diffused out of the collagen matrix slower than the latter. Importantly, collagen hydrogels loaded with the fusion protein possessed apoptotic activity in vitro and released the engineered cytokine in a controlled manner. In addition, such hydrogels reduced tumor size and extended the survival of the mouse model with xenografted tumors, which suggested a moderate antitumor activity in vivo.

show abstract

Section: ■ Discussionmentioning

confidence: 99%

Collagen Hydrogel Functionalized with Collagen-Targeting IFNA2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors

Jiang

et al. 2018

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…While several studies have shown that IFN therapy administered to patients with proven acute hepatitis C decreases the risk of chronic hepatitis C developing later [20,21], treatment is expensive and is associated with potential adverse events. Most experts recommend treatment of patients with acute hepatitis C, but with the caveat that patients be informed of their chances for spontaneous recovery (15%), and the expected side‐effects and required duration of therapy.…”

Section: Treatment Strategiesmentioning

confidence: 99%

Therapeutic modalities in hepatitis C: challenges and development

Moreno–Otero

2005

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Our understanding of the pathogenicity of hepatitis C virus (HCV) is based on patients infected chronically for >20 years. The lack of a suitable animal model, the narrow host range of the virus, and the protracted onset of liver disease induced by HCV have hampered advances in treatment. In spite of these problems, we identified patient and viral characteristics that predict responses to current therapies, including HCV genotype, viral load, body weight, age, liver histology, co-infection with HIV and treatment adherence and tolerance. Interferon (IFN) alpha was the first therapy for chronic HCV infection. The combination of IFN plus ribavirin increases sustained virological response rates compared with IFN alone. Two pegylated IFNs have been developed and are widely approved for the treatment of chronic hepatitis C: peginterferon alpha-2a (40 KD), and pegylated IFN alpha-2b (12 KD). These products have reduced systemic clearance, prolonged half-lives and reduced antigenicity compared with conventional IFN. The reduced clearance results in sustained plasma levels of the drug and allows for once-weekly dosing. Pegylated IFN alpha-2b (12 KD) has a small, linear polyethylene glycol (PEG) moiety and has an intermediate duration of activity; peginterferon alpha-2a (40 KD) incorporates a large, branched-chain PEG moiety and has a longer half-life than both conventional IFN alpha and pegylated IFN alpha-2b (12 KD). The combination of a pegylated IFN plus ribavirin significantly increases sustained virological response rates compared with conventional IFN plus ribavirin in patients with chronic hepatitis C and is now recognized as the standard of care for these patients.

show abstract

Antivirale Therapie der chronischen Virushepatitis

Manns¹

2001

Der Internist

View full text Add to dashboard Cite

Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection

Cited by 4 publications

References 0 publications

Collagen Hydrogel Functionalized with Collagen-Targeting IFNA2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors

Collagen Hydrogel Functionalized with Collagen-Targeting IFNA2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors

Therapeutic modalities in hepatitis C: challenges and development

Antivirale Therapie der chronischen Virushepatitis

Contact Info

Product

Resources

About